- Home
- LILA vs ANAB Comparison
LILA vs ANAB Comparison
Compare LILA & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILA | ANAB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LILA | ANAB |
|---|---|---|
| Price | $8.88 | $54.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $13.00 | ★ $71.67 |
| AVG Volume (30 Days) | 345.7K | ★ 409.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.55 | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,442,200,000.00 | $234,603,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.23 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $4.77 | $17.11 |
| 52 Week High | $9.04 | $73.30 |
Technical Indicators
Market Signals| Indicator | LILA | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 41.00 |
| Support Level | $7.15 | $53.46 |
| Resistance Level | $9.04 | $58.62 |
| Average True Range (ATR) | 0.19 | 2.32 |
| MACD | -0.00 | -0.33 |
| Stochastic Oscillator | 98.20 | 6.87 |
Price Performance
Historical ComparisonAbout LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).